HIGHGATE Genetics is on a mission to extend the power of genomic cancer risk assessment and management to more patients and families.
THE NEED
Genetic information is now an important consideration in the care of most cancer patients.
Germline testing is expanding rapidly, and impacts therapeutic decisions, risk assessment, and risk management in patients and their family members. Tumor and circulating tumor DNA testing are well established but still underutilized, and in some cases not well understood. Universal paired tumor-germline testing is in use now in major cancer centers and is on the horizon for others. Pharmacogenomics has already assumed its place in oncology drug management.
Many oncology practices and hospital-based cancer programs have yet to optimize genomic cancer risk management and as a result are underutilizing a major component of cancer care, market competitiveness, and practice growth.
Significant barriers to pracitioner-led germline genetic testing include:
- Practitioner uncertainty about genetics knowledge
- Workflow issues involving test ordering and pedigree analysis
- Concern about follow-up on positive results
- Limited genetics workforce
- Understanding required program structure and business impact
HIGHGATE Genetics provides the tools to overcome these barriers, leading to better patient care, improved competitive position, and enhanced business performance.
